CG Oncology, Inc. $CGON Stock Holdings Decreased by AMI Asset Management Corp

AMI Asset Management Corp lowered its position in shares of CG Oncology, Inc. (NASDAQ:CGON) by 51.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 20,129 shares of the company’s stock after selling 21,080 shares during the quarter. AMI Asset Management Corp’s holdings in CG Oncology were worth $1,362,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Comerica Bank lifted its holdings in CG Oncology by 100.4% in the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after acquiring an additional 515 shares during the last quarter. LPL Financial LLC grew its stake in shares of CG Oncology by 9.8% in the fourth quarter. LPL Financial LLC now owns 6,201 shares of the company’s stock worth $257,000 after purchasing an additional 551 shares in the last quarter. Whittier Trust Co. of Nevada Inc. bought a new position in CG Oncology in the 4th quarter valued at about $27,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of CG Oncology by 33.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock valued at $163,000 after acquiring an additional 972 shares in the last quarter. Finally, Swiss National Bank boosted its stake in CG Oncology by 1.5% during the 3rd quarter. Swiss National Bank now owns 81,300 shares of the company’s stock valued at $3,275,000 after purchasing an additional 1,200 shares in the last quarter. 26.56% of the stock is currently owned by institutional investors.

CG Oncology Stock Performance

Shares of CGON stock opened at $73.73 on Tuesday. The firm’s 50 day moving average price is $64.55 and its two-hundred day moving average price is $58.34. CG Oncology, Inc. has a 52-week low of $23.65 and a 52-week high of $75.50. The stock has a market cap of $6.50 billion, a PE ratio of -31.64 and a beta of 0.31.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million during the quarter, compared to the consensus estimate of $0.45 million. As a group, sell-side analysts predict that CG Oncology, Inc. will post -2.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CGON. JPMorgan Chase & Co. lifted their price objective on shares of CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Royal Bank Of Canada upped their price target on CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Truist Financial reiterated a “buy” rating and issued a $82.00 target price (up from $77.00) on shares of CG Oncology in a research report on Thursday, May 14th. Wall Street Zen cut shares of CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Finally, HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of CG Oncology in a research note on Monday, May 18th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $81.73.

Insider Activity at CG Oncology

In other news, Director Brian Guan-Chyun Liu acquired 371,085 shares of CG Oncology stock in a transaction dated Thursday, June 25th. The stock was bought at an average cost of $66.87 per share, with a total value of $24,814,453.95. Following the completion of the transaction, the director directly owned 1,886,236 shares of the company’s stock, valued at approximately $126,132,601.32. This represents a 24.49% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James Mulay sold 1,964 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $60.12, for a total transaction of $118,075.68. Following the completion of the sale, the director directly owned 654 shares in the company, valued at approximately $39,318.48. This represents a 75.02% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 28,564 shares of company stock valued at $1,986,532. 4.80% of the stock is owned by corporate insiders.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.